Positive data result in positive share price movements – something of a novelty in the current market.
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
Trading well below cash hasn’t stopped Cullinan from extracting more from Otsuka, when a low-ball buyout might have been on the cards.
The failure of Skyscraper-01 calls into question Roche’s vast investment in Tigit blockade, but is there broader significance?
Biohaven looks to have timed its exit well, giving investors more reason to cheer the $11.6bn buyout.
As biopharma awaits Roche’s pivotal Skyscraper-01 data Arcus gives its investors some more tea leaves to read.